NCT04065399

Open on CT.gov ↗

Primary endpoint added: Number of participants with dose-limiting toxicities (DLTs) (Phase 1) — PHASE1
NCT04065399 • Phase 1
Enrollment 413→447 (8%) — PHASE1
NCT04065399 • Phase 1 • Enrollment 413→447 (+8%)